Clinical Trial: NCT00515554
HD18 for Advanced Stages in Hodgkins Lymphoma
Status:
COMPLETEDPhase:
Phase 3| Lead Sponsor: | University of Cologne |
| Information Provided By: | University of Cologne |
| Last Update Posted: | 2020-11-13 |
Study Overview
Brief Summary
This study is designed to test:
- in patients with negative positron-emission tomography (PET) after 2 cycles of BEACOPPesc chemotherapy: whether the number of cycles can be reduced without compromising progression free survival (PFS) (2 further cycles vs. 6 further cycles)
- for patients with positive PET after 2 cycles: whether intensifying BEACOPPesc chemotherapy by adding Rituximab improves PFS.
Official Title
Conditions
Hodgkins Lymphoma
Intervention / Treatment
- Drug: Rituximab
- Drug: BEACOPP escalated
Other Study ID Numbers
- HD18
Start Date (Actual)
2008-05
Primary Completion Date (Actual)
2019-07
Study Completion Date (Actual)
2020-07
Enrollment (Actual)
1500
Study Type
Interventional
Phase
Phase 3
| Lead Sponsor: | University of Cologne |
| Information Provided By: | University of Cologne |
| Last Update Posted: | 2020-11-13 |
Study Overview
Brief Summary
This study is designed to test:
- in patients with negative positron-emission tomography (PET) after 2 cycles of BEACOPPesc chemotherapy: whether the number of cycles can be reduced without compromising progression free survival (PFS) (2 further cycles vs. 6 further cycles)
- for patients with positive PET after 2 cycles: whether intensifying BEACOPPesc chemotherapy by adding Rituximab improves PFS.
Official Title
Conditions
Hodgkins Lymphoma
Intervention / Treatment
- Drug: Rituximab
- Drug: BEACOPP escalated
Other Study ID Numbers
- HD18
Start Date (Actual)
2008-05
Primary Completion Date (Actual)
2019-07
Study Completion Date (Actual)
2020-07
Enrollment (Actual)
1500
Study Type
Interventional
Phase
Phase 3